Bianca M. L. Stelten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bianca M. L. Stelten has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Aad Verrips
Canisius-Wilhelmina Hospital, Department of Neurology
5 shared publications Aad Verrips
From the Department of Neurology (B.M.L.S.), Catharina Hospital, Eindhoven; Department of Radiology (G.J.L.N.), Haaglanden Medical Center, The Hague; Department of Neurology (E.H., A.V.), Canisius Wilhelmina Hospital; and Department of Laboratory Medicine (L.A.J.K., R.A.W.), Translational Metabolic Laboratory, Radboud University Medical Center, Nijmegen, the Netherlands
4 shared publications- Ron Allan Wevers
Translational Metabolic Laboratory, Department Human Genetics, Radboud University Medical Centre, Nijmegen, the Netherlands
3 shared publications - Hidde H. Huidekoper
Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Sophia Children’s Hospital, Rotterdam, The Netherlands
2 shared publications Ron A. Wevers
From the Department of Neurology (B.M.L.S.), Catharina Hospital, Eindhoven; Department of Radiology (G.J.L.N.), Haaglanden Medical Center, The Hague; Department of Neurology (E.H., A.V.), Canisius Wilhelmina Hospital; and Department of Laboratory Medicine (L.A.J.K., R.A.W.), Translational Metabolic Laboratory, Radboud University Medical Center, Nijmegen, the Netherlands
2 shared publicationsA. D. Marais
Chemical pathology University of Cape Town Cape Town South Africa
1 shared publication
Latest Publications
- Open Access
- 10 June 2026
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 59 (4) , 642-652
Percutaneous endoscopic gastrostomy with jejunal extension versus direct percutaneous endoscopic jejunostomy: patient-related outcomes and complications
Background/Aims: Percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) and direct percutaneous endoscopic jejunostomy (D-PEJ) are used for jejunal feeding or administration of levodopa-carbidopa intestinal gel in patients with Parkinson’s disease. PEG-J is currently preferred because it is technically less challenging to insert. However, comparative studies are scarce, and data on patient-reported outcomes (PROMs) are limited.Methods: In this retrospective study conducted at a referral hospital, clinical experience, adverse events (AEs), and PROMs associated with both techniques were evaluated.Results: Ninety-three patients underwent PEG-J and/or D-PEJ placement between January 1, 2010, and July 1, 2022. Patients with PEG-J required significantly more re-endoscopies per tube-year than those with D-PEJ (0.63 [standard deviation, SD, 0.72] vs. 0.27 [SD 0.50]). A total of 76.8% of PEG-J patients underwent at least one re-endoscopy (range, 0–3.85 per year), primarily due to dislocated jejunal extensions (77.4%). Tube-related AEs (including dislocation, occlusion, perforation, and ulceration) occurred significantly more often after PEG-J insertion (76.7% vs. 25.9%). Forty-five patients (48%) completed the PROM questionnaire. No statistically significant differences were found in quality of life. However, D-PEJ patients reported significantly more tube-related pain (44.4% vs. 15.9%).Conclusions: D-PEJ represents a viable alternative to PEG-J in experienced centers and should be considered when frequent complications with jejunal extensions occur.
- 10 June 2026
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 59 (4) , 642-652
Open AccessPercutaneous endoscopic gastrostomy with jejunal extension versus direct percutaneous endoscopic jejunostomy: patient-related outcomes and complications
Background/Aims: Percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) and direct percutaneous endoscopic jejunostomy (D-PEJ) are used for jejunal feeding or administration of levodopa-carbidopa intestinal gel in patients with Parkinson’s disease. PEG-J is currently preferred because it is technically less challenging to insert. However, comparative studies are scarce, and data on patient-reported outcomes (PROMs) are limited.Methods: In this retrospective study conducted at a referral hospital, clinical experience, adverse events (AEs), and PROMs associated with both techniques were evaluated.Results: Ninety-three patients underwent PEG-J and/or D-PEJ placement between January 1, 2010, and July 1, 2022. Patients with PEG-J required significantly more re-endoscopies per tube-year than those with D-PEJ (0.63 [standard deviation, SD, 0.72] vs. 0.27 [SD 0.50]). A total of 76.8% of PEG-J patients underwent at least one re-endoscopy (range, 0–3.85 per year), primarily due to dislocated jejunal extensions (77.4%). Tube-related AEs (including dislocation, occlusion, perforation, and ulceration) occurred significantly more often after PEG-J insertion (76.7% vs. 25.9%). Forty-five patients (48%) completed the PROM questionnaire. No statistically significant differences were found in quality of life. However, D-PEJ patients reported significantly more tube-related pain (44.4% vs. 15.9%).Conclusions: D-PEJ represents a viable alternative to PEG-J in experienced centers and should be considered when frequent complications with jejunal extensions occur.
- 20 October 2025
- Published by Springer Nature
- p. 209-216
Long-Term Treatment Effect in Cerebrotendinous Xanthomatosis (CTX) Depends on Age at Treatment Start
- 20 October 2025
- Published by Springer Nature
- p. 209-216
Long-Term Treatment Effect in Cerebrotendinous Xanthomatosis (CTX) Depends on Age at Treatment Start
- 21 March 2023
- Published by Springer Nature
- p. 649-654
Cerebrotendinous Xanthomatosis
- 27 September 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (13) , 559-566
Long-term MRI Findings in Patients With Cerebrotendinous Xanthomatosis Treated With Chenodeoxycholic Acid
Objectives To describe long-term follow-up brain magnetic resonance (MRI) findings in patients with cerebrotendinous xanthomatosis (CTX) treated with chenodeoxycholic acid (CDCA). Methods Out of a cohort of 79 Dutch CTX patients, we retrospectively reviewed brain MRI findings of patients at diagnosis (before start of treatment) and after long-term follow-up (7-27 years) in 12 patients. In addition, we report on 2 families with remarkable brain MRI findings. Results MRI abnormalities showed progression in all 7 patients diagnosed at 24 years or older, and only in 1 out of 5 patients diagnosed < 24 years. MRI in the other patients diagnosed < 24 years were normal at baseline and remained normal even after follow-up of more than 25 years. Total MRI scores at baseline were 2 respectively 19, and at follow-up 4 respectively 37, for patients diagnosed before or after the age of 24 years, despite comparable number of treatment years. Discussion MRI findings are fully in line with our long-term treatment effect paper, emphasizing the importance of early diagnosis and treatment in CTX. Expanding the spectrum of brain MRI findings (including the finding of a ‘posterior leukoencephalopathy’) leads to a better understanding of the heterogeneity of this treatable disease.
- 27 September 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (13) , 559-566
Long-term MRI Findings in Patients With Cerebrotendinous Xanthomatosis Treated With Chenodeoxycholic Acid
Objectives To describe long-term follow-up brain magnetic resonance (MRI) findings in patients with cerebrotendinous xanthomatosis (CTX) treated with chenodeoxycholic acid (CDCA). Methods Out of a cohort of 79 Dutch CTX patients, we retrospectively reviewed brain MRI findings of patients at diagnosis (before start of treatment) and after long-term follow-up (7-27 years) in 12 patients. In addition, we report on 2 families with remarkable brain MRI findings. Results MRI abnormalities showed progression in all 7 patients diagnosed at 24 years or older, and only in 1 out of 5 patients diagnosed < 24 years. MRI in the other patients diagnosed < 24 years were normal at baseline and remained normal even after follow-up of more than 25 years. Total MRI scores at baseline were 2 respectively 19, and at follow-up 4 respectively 37, for patients diagnosed before or after the age of 24 years, despite comparable number of treatment years. Discussion MRI findings are fully in line with our long-term treatment effect paper, emphasizing the importance of early diagnosis and treatment in CTX. Expanding the spectrum of brain MRI findings (including the finding of a ‘posterior leukoencephalopathy’) leads to a better understanding of the heterogeneity of this treatable disease.
- Open Access
- 6 August 2021
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 16 (1) , 1-18
Expert opinion on diagnosing, treating and managing patients with cerebrotendinous xanthomatosis (CTX): a modified Delphi study
Background: Cerebrotendinous xanthomatosis (CTX) is a rare, chronic, progressive, neurodegenerative disorder requiring life-long care. Patients with CTX often experience a diagnostic delay. Although early diagnosis and treatment initiation can improve symptoms and prognosis, a standardised approach to diagnosis, treatment and management of patients is not yet established.Aim: To assess expert opinion on best care practices for patients with CTX using a modified Delphi method.Methods: A multidisciplinary group of healthcare professionals with expertise in CTX responded to a 3-round online questionnaire (n = 10 in Rounds 1 and 2; n = 9 in Round 3), containing questions relating to the diagnosis, treatment, monitoring, multidisciplinary care and prognosis of patients with CTX. Determination of consensus achievement was based on a pre-defined statistical threshold of ≥ 70% Delphi panellists selecting 1–2 (disagreement) or 5–6 (agreement) for 6-point Likert scale questions, or ≥ 70% Delphi panellists choosing the same option for ranking and proportion questions.Results: Of the Round 1 (n = 22), Round 2 (n = 32) and Round 3 (n = 26) questions for which consensus was assessed, 59.1%, 21.9% and 3.8% reached consensus, respectively. Consensus agreement that genetic analyses and/or determination of serum cholestanol levels should be used to diagnose CTX, and dried bloodspot testing should facilitate detection in newborns, was reached. Age at diagnosis and early treatment initiation (at birth, where possible) were considered to have the biggest impact on treatment outcomes. All panellists agreed that chenodeoxycholic acid (CDCA) is a lifetime replacement therapy which, if initiated early, can considerably improve prognosis as it may be capable of reversing the pathophysiological process in CTX. No consensus was reached on the value of cholic acid therapy alone. Monitoring patients through testing plasma cholestanol levels and neurologic examination was recommended, although further research regarding monitoring treatment and progression of the disease is required. Neurologists and paediatricians/metabolic specialists were highlighted as key clinicians that should be included in the multidisciplinary team involved in patients’ care.Conclusions: The results of this study provide a basis for standardisation of care and highlight key areas where further research is needed to inform best practices for the diagnosis, treatment and management of patients with CTX.
- 6 August 2021
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 16 (1) , 1-18
Open AccessExpert opinion on diagnosing, treating and managing patients with cerebrotendinous xanthomatosis (CTX): a modified Delphi study
Background: Cerebrotendinous xanthomatosis (CTX) is a rare, chronic, progressive, neurodegenerative disorder requiring life-long care. Patients with CTX often experience a diagnostic delay. Although early diagnosis and treatment initiation can improve symptoms and prognosis, a standardised approach to diagnosis, treatment and management of patients is not yet established.Aim: To assess expert opinion on best care practices for patients with CTX using a modified Delphi method.Methods: A multidisciplinary group of healthcare professionals with expertise in CTX responded to a 3-round online questionnaire (n = 10 in Rounds 1 and 2; n = 9 in Round 3), containing questions relating to the diagnosis, treatment, monitoring, multidisciplinary care and prognosis of patients with CTX. Determination of consensus achievement was based on a pre-defined statistical threshold of ≥ 70% Delphi panellists selecting 1–2 (disagreement) or 5–6 (agreement) for 6-point Likert scale questions, or ≥ 70% Delphi panellists choosing the same option for ranking and proportion questions.Results: Of the Round 1 (n = 22), Round 2 (n = 32) and Round 3 (n = 26) questions for which consensus was assessed, 59.1%, 21.9% and 3.8% reached consensus, respectively. Consensus agreement that genetic analyses and/or determination of serum cholestanol levels should be used to diagnose CTX, and dried bloodspot testing should facilitate detection in newborns, was reached. Age at diagnosis and early treatment initiation (at birth, where possible) were considered to have the biggest impact on treatment outcomes. All panellists agreed that chenodeoxycholic acid (CDCA) is a lifetime replacement therapy which, if initiated early, can considerably improve prognosis as it may be capable of reversing the pathophysiological process in CTX. No consensus was reached on the value of cholic acid therapy alone. Monitoring patients through testing plasma cholestanol levels and neurologic examination was recommended, although further research regarding monitoring treatment and progression of the disease is required. Neurologists and paediatricians/metabolic specialists were highlighted as key clinicians that should be included in the multidisciplinary team involved in patients’ care.Conclusions: The results of this study provide a basis for standardisation of care and highlight key areas where further research is needed to inform best practices for the diagnosis, treatment and management of patients with CTX.
- 8 April 2021
- Published by Wiley in Journal of Internal Medicine
- Vol. 290 (5) , 1039-1047
Cerebrotendinous xanthomatosis without neurological involvement
Background: Cerebrotendinous xanthomatosis (CTX) is an autosomal recessively inherited inborn error of metabolism. Neurological symptoms are considered to be a clinical hallmark of untreated adult patients. We describe a ‘milder CTX phenotype’, without neurological involvement.Methods: We performed a retrospective patient file study in 79 genetically confirmed Dutch patients with CTX (55 patients aged ≥ 21 years) to study the clinical heterogeneity of CTX. We studied the frequency of adult patients with CTX without neurological involvement at diagnosis, in our Dutch cohort, and included a family from South Africa and patients from Italy, USA, Chile and Asia from the literature.Results: In total, we describe 19 adult patients with CTX from 16 independent families, without neurological symptoms at diagnosis. A relatively small percentage (21%, n = 4) had a history of cataract. The majority, 84% (n = 16), presented with tendon xanthomas as the sole or predominant feature. The majority of patients showed increased plasma cholesterol levels. No correlation was found between this ‘milder phenotype’, the cholestanol levels and the CYP27A1 genotype. In addition, we describe three novel mutations in the CYP27A1 gene.Conclusions: This study shows the clinical heterogeneity of CTX, highlighting the existence of a ‘milder phenotype’, that is without neurological involvement at diagnosis. Adult patients with CTX may present with tendon xanthomas as the sole or predominant feature, mimicking familial hypercholesterolemia. It is important to realize that the absence of neurological symptoms does not rule out the development of future neurological symptoms. As CTX is a treatable disorder, early diagnosis and initiation of treatment when additional clinical signs occur is therefore essential.
- 8 April 2021
- Published by Wiley in Journal of Internal Medicine
- Vol. 290 (5) , 1039-1047
Cerebrotendinous xanthomatosis without neurological involvement
Background: Cerebrotendinous xanthomatosis (CTX) is an autosomal recessively inherited inborn error of metabolism. Neurological symptoms are considered to be a clinical hallmark of untreated adult patients. We describe a ‘milder CTX phenotype’, without neurological involvement.Methods: We performed a retrospective patient file study in 79 genetically confirmed Dutch patients with CTX (55 patients aged ≥ 21 years) to study the clinical heterogeneity of CTX. We studied the frequency of adult patients with CTX without neurological involvement at diagnosis, in our Dutch cohort, and included a family from South Africa and patients from Italy, USA, Chile and Asia from the literature.Results: In total, we describe 19 adult patients with CTX from 16 independent families, without neurological symptoms at diagnosis. A relatively small percentage (21%, n = 4) had a history of cataract. The majority, 84% (n = 16), presented with tendon xanthomas as the sole or predominant feature. The majority of patients showed increased plasma cholesterol levels. No correlation was found between this ‘milder phenotype’, the cholestanol levels and the CYP27A1 genotype. In addition, we describe three novel mutations in the CYP27A1 gene.Conclusions: This study shows the clinical heterogeneity of CTX, highlighting the existence of a ‘milder phenotype’, that is without neurological involvement at diagnosis. Adult patients with CTX may present with tendon xanthomas as the sole or predominant feature, mimicking familial hypercholesterolemia. It is important to realize that the absence of neurological symptoms does not rule out the development of future neurological symptoms. As CTX is a treatable disorder, early diagnosis and initiation of treatment when additional clinical signs occur is therefore essential.
- Open Access
- 20 December 2019
- Published by Springer Nature in Neurological Sciences
- Vol. 41 (4) , 943-949
The safety and effectiveness of chenodeoxycholic acid treatment in patients with cerebrotendinous xanthomatosis: two retrospective cohort studies
Objective: To evaluate the safety and effectiveness of chenodeoxycholic acid (CDCA) treatment in patients with cerebrotendinous xanthomatosis (CTX).Methods: Two retrospective cohort studies were conducted in CTX patients who underwent CDCA treatment: one in the Netherlands (NL; CDCA-STUK-15-001) and one in Italy (IT; CDCA-STRCH-CR-14-001). Eligible patients were aged 2–75 years, had been diagnosed with CTX, and were treated with CDCA orally for ≥1 year. The impact of CDCA treatment on biochemical markers (including serum cholestanol levels) and disease signs and symptoms were assessed, in addition to the safety and tolerability of CDCA treatment.Results: A total of 35 patients were screened in the NL study and were diagnosed with CTX at 25.6 (± 13.7 SD) years on average. These patients were treated with CDCA and followed up for a median of 9.00 (range: 0.4–26.3) years. In addition, 28 patients were enrolled in the IT study and were diagnosed at 35.0 (± 11.4 SD) years on average (median duration of CDCA treatment: 5.75 [range: 0.0–25.0] years). Signs and symptoms of disease resolved, improved, or remained stable in many patients, with concomitant improvements in biochemical marker levels (serum cholestanol,p< 0.001; 7α-hydroxy-4-cholesten-3-one,p< 0.001 [IT study]).Conclusions: The outcomes of these retrospective cohort studies indicate that CDCA is effective in the long-term treatment of CTX, with an acceptable safety profile.
- 20 December 2019
- Published by Springer Nature in Neurological Sciences
- Vol. 41 (4) , 943-949
Open AccessThe safety and effectiveness of chenodeoxycholic acid treatment in patients with cerebrotendinous xanthomatosis: two retrospective cohort studies
Objective: To evaluate the safety and effectiveness of chenodeoxycholic acid (CDCA) treatment in patients with cerebrotendinous xanthomatosis (CTX).Methods: Two retrospective cohort studies were conducted in CTX patients who underwent CDCA treatment: one in the Netherlands (NL; CDCA-STUK-15-001) and one in Italy (IT; CDCA-STRCH-CR-14-001). Eligible patients were aged 2–75 years, had been diagnosed with CTX, and were treated with CDCA orally for ≥1 year. The impact of CDCA treatment on biochemical markers (including serum cholestanol levels) and disease signs and symptoms were assessed, in addition to the safety and tolerability of CDCA treatment.Results: A total of 35 patients were screened in the NL study and were diagnosed with CTX at 25.6 (± 13.7 SD) years on average. These patients were treated with CDCA and followed up for a median of 9.00 (range: 0.4–26.3) years. In addition, 28 patients were enrolled in the IT study and were diagnosed at 35.0 (± 11.4 SD) years on average (median duration of CDCA treatment: 5.75 [range: 0.0–25.0] years). Signs and symptoms of disease resolved, improved, or remained stable in many patients, with concomitant improvements in biochemical marker levels (serum cholestanol,p< 0.001; 7α-hydroxy-4-cholesten-3-one,p< 0.001 [IT study]).Conclusions: The outcomes of these retrospective cohort studies indicate that CDCA is effective in the long-term treatment of CTX, with an acceptable safety profile.
- 8 January 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (2) , e83-e95
Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start
Objective To evaluate the effect of chenodeoxycholic acid treatment on disease progression in cerebrotendinous xanthomatosis (CTX). Methods In this retrospective cohort study, we report the clinical long-term follow-up characteristics of 56 Dutch patients with CTX. Age at diagnosis was correlated with clinical characteristics and with the course of modified Rankin Scale (mRS) and Expanded Disability Status Scale (EDSS) scores at follow-up. Results Median follow-up time was 8 years (6 months–31.5 years). Patients diagnosed and treated before the age of 24 years had a significantly better outcome at follow-up. When considering only patients with a good treatment adherence (n = 43), neurologic symptoms, if present, disappeared in all patients who were diagnosed before the age of 24 and treated since. Furthermore, treatment prevented the development of new neurologic symptoms during follow-up. In contrast, 61% of the patients diagnosed and treated after the age of 24 showed deterioration of the neurologic symptoms, with parkinsonism as a treatment-resistant feature. There was an improvement or stabilization in favor of patients diagnosed and treated before the age of 24 compared to those treated after the age of 24: 100% vs 58% for mRS scores and 100% vs 50% for EDSS scores, respectively. Conclusions Treatment start at an early age can reverse and even prevent the development of neurologic symptoms in CTX. This study emphasizes the importance of early diagnosis in CTX and provides a rationale to include CTX in newborn screening programs.
- 8 January 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (2) , e83-e95
Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start
Objective To evaluate the effect of chenodeoxycholic acid treatment on disease progression in cerebrotendinous xanthomatosis (CTX). Methods In this retrospective cohort study, we report the clinical long-term follow-up characteristics of 56 Dutch patients with CTX. Age at diagnosis was correlated with clinical characteristics and with the course of modified Rankin Scale (mRS) and Expanded Disability Status Scale (EDSS) scores at follow-up. Results Median follow-up time was 8 years (6 months–31.5 years). Patients diagnosed and treated before the age of 24 years had a significantly better outcome at follow-up. When considering only patients with a good treatment adherence (n = 43), neurologic symptoms, if present, disappeared in all patients who were diagnosed before the age of 24 and treated since. Furthermore, treatment prevented the development of new neurologic symptoms during follow-up. In contrast, 61% of the patients diagnosed and treated after the age of 24 showed deterioration of the neurologic symptoms, with parkinsonism as a treatment-resistant feature. There was an improvement or stabilization in favor of patients diagnosed and treated before the age of 24 compared to those treated after the age of 24: 100% vs 58% for mRS scores and 100% vs 50% for EDSS scores, respectively. Conclusions Treatment start at an early age can reverse and even prevent the development of neurologic symptoms in CTX. This study emphasizes the importance of early diagnosis in CTX and provides a rationale to include CTX in newborn screening programs.
- 1 January 2019
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 58, 12-16
Movement disorders in cerebrotendinous xanthomatosis
- 1 January 2019
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 58, 12-16
Movement disorders in cerebrotendinous xanthomatosis
- 11 September 2017
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 41 (4) , 641-646
Autism spectrum disorder: an early and frequent feature in cerebrotendinous xanthomatosis
Background: Cerebrotendinous xanthomatosis (CTX) is an autosomal recessively inherited inborn error of metabolism (IEM) due to mutations in the CYP27A1 gene. The clinical picture ranges from being nearly asymptomatic in early childhood, up to severe disability at adult age. Infantile‐onset diarrhea and juvenile‐onset cataract are the earliest symptoms in childhood. In the current study, we evaluated the presence of autism spectrum disorder (ASD) in a large cohort of CTX patients.Methods: We performed a retrospective patient file study in 77 genetically confirmed Dutch CTX patients to determine the frequency of ASD. In addition, we compared plasma cholestanol levels in CTX patients with and without a diagnosis of ASD and tried to establish a relation between CYP27A1 genotype and ASD.Results: In our CTX cohort, 10 patients (13%; nine pediatric and one adult) with ASD were identified. At the time of diagnosis of ASD, most patients only exhibited symptoms of diarrhea and/or intellectual disability without signs of cataract or neurological symptoms. No correlation was found between the presence of ASD and the level of cholestanol or CYP27A1 genotype. The behavioral problems stabilized or improved after treatment initiation with chenodeoxycholic acid (CDCA) in all pediatric patients.Conclusions: We conclude that ASD is an early and probably underestimated frequent feature in CTX. Metabolic screening for CTX should be performed in patients with ASD when accompanied by diarrhea, intellectual disability, juvenile cataract, and/or neurological involvement. Early recognition allows for earlier initiation of specific treatment and will improve clinical outcome. Our results add CTX to the list of treatable IEMs associated with ASD.
- 11 September 2017
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 41 (4) , 641-646
Autism spectrum disorder: an early and frequent feature in cerebrotendinous xanthomatosis
Background: Cerebrotendinous xanthomatosis (CTX) is an autosomal recessively inherited inborn error of metabolism (IEM) due to mutations in the CYP27A1 gene. The clinical picture ranges from being nearly asymptomatic in early childhood, up to severe disability at adult age. Infantile‐onset diarrhea and juvenile‐onset cataract are the earliest symptoms in childhood. In the current study, we evaluated the presence of autism spectrum disorder (ASD) in a large cohort of CTX patients.Methods: We performed a retrospective patient file study in 77 genetically confirmed Dutch CTX patients to determine the frequency of ASD. In addition, we compared plasma cholestanol levels in CTX patients with and without a diagnosis of ASD and tried to establish a relation between CYP27A1 genotype and ASD.Results: In our CTX cohort, 10 patients (13%; nine pediatric and one adult) with ASD were identified. At the time of diagnosis of ASD, most patients only exhibited symptoms of diarrhea and/or intellectual disability without signs of cataract or neurological symptoms. No correlation was found between the presence of ASD and the level of cholestanol or CYP27A1 genotype. The behavioral problems stabilized or improved after treatment initiation with chenodeoxycholic acid (CDCA) in all pediatric patients.Conclusions: We conclude that ASD is an early and probably underestimated frequent feature in CTX. Metabolic screening for CTX should be performed in patients with ASD when accompanied by diarrhea, intellectual disability, juvenile cataract, and/or neurological involvement. Early recognition allows for earlier initiation of specific treatment and will improve clinical outcome. Our results add CTX to the list of treatable IEMs associated with ASD.